Beyond AirXAIR
Recorded

Beyond Air 2027 Q2 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ2 2027Duration28 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, everyone, and welcome to the Beyond Air financial results call for the quarter ended September 30, 2026. At this time, participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Now, I would like to turn the call over to Corey Davis, LifeSci Advisors.

Corey DavisManaging Director

Please go ahead. Thank you, operator.

Corey DavisManaging Director

Good afternoon, everyone, and thank you for joining us. Earlier today, we issued a press release announcing the operational highlights and financial results for Beyond Air's quarter ended September 30, 2026. A copy of this press release can be found on our website, beyondair.net, under the News and Events section. Before we begin, I'd like to remind everyone that we will be making comments and various remarks about future expectations, plans, and prospects, which constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.

Corey DavisManaging Director

We encourage everyone to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's most recent Form 10-Q and Form 10-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, beyondair.net. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 11, 2026. Beyond Air undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call. With that, I'll turn it over to Robert Goodman, Chief Executive Officer of Beyond Air. Bob, go ahead. The floor is yours.

Bob GoodmanCEO

Thanks, Corey, and good afternoon, everyone. I'm pleased to speak with you today and provide an update on what has been a productive and meaningful period for Beyond Air. With me today is Dan Moorhead, our Chief Financial Officer. I'll begin with an update on our recent activities and commercial execution for LungFit PH before turning the call over to Dan to discuss our financial results for the quarter ended September 30, 2026. We'll then open the call for questions. Throughout the third quarter, we continued to focus on positioning the company for its next phase of growth. As we prepare for the planned commercial launch of our second-generation LungFit PH system, pending FDA approval, our priorities remain focused on expanding market penetration, deepening relationships with hospitals and health systems, and growing our commercial pipeline while building on the momentum of our first-generation LungFit PH system.

Bob GoodmanCEO

These efforts contributed to record quarterly revenue of $2.3 million in the September quarter, up approximately 28% year-over-year and 31% from the June quarter. We achieved this growth while maintaining financial discipline and prioritizing resources to support commercial execution and preparations for the potential launch of second-generation LungFit PH. Underlying these results is the progress we are making in expanding market penetration and converting hospital interest into signed customer agreements that support recurring revenue over multiple years. Our in-house sales team is building these relationships supported by national GPO agreements that broaden our reach across hospitals and hospital systems. Our U.S. commercial pipeline is expanding, reflecting accelerated demand for our first-generation system and strong receptivity to our technology and operational efficiencies it offers.

Bob GoodmanCEO

We are especially pleased with the pace of new account wins and the rate of renewals, which speak to the acceptance of our innovative technology and delivery of iNO, resulting in exceptional customer satisfaction, which gives us a foundation to build on as we prepare for the potential launch of the second-generation LungFit PH. International distribution is another important opportunity for growth. We have partnerships in place covering more than 40 countries, and international sales during the quarter were one of the highest to date. Looking ahead, pending FDA approval, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth. The system is smaller, has reduced weight, simplified operation, longer service intervals, and expanded operational flexibility. Our PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground.

Bob GoodmanCEO

Turning to the regulatory process, our PMA supplement for the second-generation LungFit PH remains under FDA review. We remain encouraged by the progress we are making toward completing the remaining steps in the review process. We expect to complete our audit readiness process in mid-December. The system would then remain subject to FDA inspections and final approval. The timing and outcome of these steps remain subject to the FDA's review. We are excited to be at these final steps of the process. As I mentioned a minute ago, the second-generation LungFit adds transport capability. This is important as it will enable us to serve as a single-source nitric oxide provider across routine care and patient transport, which is the current standard across most U.S. hospital systems. This will strengthen our competitive position and support broader adoption of our cylinder-free technology.

Bob GoodmanCEO

Turning to another development program within our LungFit platform, LungFit GO received FDA Breakthrough Device Designation during the quarter for the treatment of nontuberculous mycobacterial pulmonary disease, or NTM PD. We believe this designation underscores the significant unmet need to NTM PD and builds upon clinical data generated with LungFit GO in this patient population. While we are encouraged by this designation, we do not currently plan to allocate resources to further development of LungFit GO in 2027. Our focus remains on commercial execution for LungFit PH and preparations for the launch of our second-generation system, pending FDA approval. Let me now provide a brief update on our two indirect subsidiaries focused on development programs outside of our core LungFit business. During the September quarter, we entered into a definitive agreement under which UNIVO Pharmaceutical Industries would acquire our controlling interest in NeuroNOS Israel.

Bob GoodmanCEO

The transaction is intended to provide NeuroNOS with dedicated resources, funding, and strategic focus to advance its development programs. In terms of Beyond Cancer, we are evaluating potential development partnerships and other strategic arrangements to support continued advancements of its pipeline while maintaining Beyond Air's focus and resource allocation on the commercialization of LungFit PH. Before turning the call over to Dan, I want to emphasize how encouraged we are by the progress we are making with the current LungFit PH offering and the foundation we are strengthening for the potential launch of our second-generation system, pending FDA approval. With this progress, we are reaffirming our revenue guidance of $8 million for calendar year 2026, which excludes revenue from the second-generation system. We are also reaffirming our revenue guidance of $16 million-$18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending FDA approval.

Bob GoodmanCEO

With that, I will turn the call over to Dan for a review of our financial results.

Dan MoorheadCFO

Dan? Thanks, Bob, and good afternoon, everyone.

Dan MoorheadCFO

Let me take this time to walk through our financial results for the quarter ended September 30th, 2026. Revenue for the quarter was $2.3 million compared with $1.8 million for the same period last year. This represents growth of approximately 28% year-over-year and 31% from the June 2026 quarter. Gross margin for the quarter was approximately 8% compared with negative 16% for the same period last year. Gross profit was $200,000 compared with a gross loss of $300,000 in the prior year quarter. Research and development expenses were $1.6 million compared with $2.5 million for the same period last year. The decrease was primarily attributed to lower costs related to the second-generation LungFit PH, as the majority of the development is complete.

Dan MoorheadCFO

Selling, general, and administrative expenses were $4.6 million compared with $4.9 million for the same period last year. The decrease was attributed primarily to lower stock-based compensation costs, partially offset by increased salaries in our sales organization as we build out our commercial team. Other expense for the three months ended September 30th, 2026, was $2.2 million as compared to other expense of $600,000 for the three months ended September 30th, 2025. The increase in expense was attributed primarily to an increase in interest expense and a charge for scrap materials.

Dan MoorheadCFO

Net loss attributed to common stockholders of Beyond Air for the three months ended September 30, 2026, was $7.8 million, or a loss of $3.76 per basic and diluted share, compared with a net loss of $7.9 million, or a loss of $24.98 per basic and diluted share for the three months ended September 30, 2025. As of September 30, 2026, we reported cash equivalents, restricted cash, and marketable securities of $18.5 million, which includes $2.7 million of cash held by NeuroNOS, which is shown within current assets held for sale on the balance sheet, and also includes $700,000 held by Beyond Cancer. This total also includes $4.8 million of restricted cash. As a reminder, we are transitioning our fiscal year end from March 31 to December 31, effective December 31, 2026.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day